Skip to main content
  • Saved

made a Post

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy - PubMed

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33722854/

doi: 10.1158/1535-7163.MCT-20-0462. Online ahead of print. 1 Research, Mirati Therapeutics (United States). 2 cancer center, New York University School of Medicine. 3 Research - Biology, Mirati Therapeutics (United States). 4 The University of Texas MD Anderson Cancer Center. 5 Perlmutter Cancer Center, New York University Langone Medical Center.